Zomedica Enhances TRUFORMA(R) Platform With Launch of Advanced Canine Cortisol Assay
Zomedica announced the launch of an enhanced canine cortisol assay for its TRUFORMA in-clinic diagnostic platform. The upgraded assay improves precision and accuracy, important for critical veterinary tests like the Low Dose Dexamethasone suppression test. This enhancement strengthens TRUFORMA's market position by enabling rapid in-house diagnostics, eliminating the need for external lab testing and offering immediate results, enhancing patient care and operational efficiency. Zomedica targets a $1.5 billion annual recurring revenue opportunity in the US with this platform.
The dynamic range of the cortisol assay has been improved by over 45%, facilitating better monitoring of conditions like Cushing's disease. The company began shipping the new assay earlier this month, reflecting its commitment to optimizing field performance based on customer feedback.
- Improved precision and accuracy of the canine cortisol assay.
- Enhancement strengthens TRUFORMA's market position.
- Enables rapid in-house diagnostics.
- Eliminates delays associated with external lab testing.
- Addresses a $1.5 billion annual recurring revenue opportunity in the US.
- Enhancements improve monitoring of conditions like Cushing's disease with a 45% increase in dynamic range.
- Dependence on customer feedback for optimization suggests initial shortcomings.
- Ongoing need for investments in R&D to remain competitive.
Insights
The launch of the enhanced canine cortisol assay for Zomedica's TRUFORMA platform represents a significant development in the veterinary diagnostics market. The improved precision and accuracy address a critical need for veterinarians who require reliable in-clinic testing. This can translate to better management of conditions like Cushing's disease, which is highly prevalent in dogs.
The in-house diagnostic capability of TRUFORMA, offering results comparable to reference labs, not only enhances patient care but also streamlines clinic operations by reducing wait times for test results. The ability to conduct tests such as the Low Dose Dexamethasone suppression test on-site is especially valuable. This positions TRUFORMA as a highly competitive product in the veterinary space, where timely and accurate diagnostics are essential. The estimated $1.5 billion market opportunity in the US alone underscores the platform’s potential financial impact.
For retail investors, this development suggests that Zomedica is focused on enhancing its product offerings, potentially driving higher adoption rates among veterinary practices. The expansion of the assay’s dynamic range by 45% further solidifies its utility and market appeal.
Zomedica's operational improvement through the enhanced cortisol assay is strategically significant. For a publicly traded company, such innovations can drive revenue growth by increasing the utility and adoption rate of its flagship product, TRUFORMA. The immediate implementation and shipping of the new assay to customers indicate Zomedica's readiness to capitalize on this improvement in the short term.
The mention of a $1.5 billion annual recurring revenue opportunity highlights the overall market potential. Investors should note that continuous improvements and product optimizations can foster sustained growth and market penetration. The expanded dynamic range and enhanced precision add value, making the TRUFORMA platform more attractive to veterinary clinics aiming for efficiency and accurate diagnostics.
In terms of financial performance, such enhancements typically lead to a positive impact on revenue streams and might influence market perceptions positively. The focus on heavily used assays also suggests a higher frequency of use, leading to potentially higher sales volumes.
Improved precision and greater accuracy of heavily used assay strengthens market potential for flagship in-clinic diagnostic platform
ANN ARBOR, MI / ACCESSWIRE / May 29, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the launch of its improved canine cortisol assay for the TRUFORMA in-clinic biosensor testing platform. The cortisol assay, one of the most frequently used tests on the platform, now features significant improvements that enhance its precision and accuracy. Zomedica began shipping the new assay to customers earlier this month.
"Since the commercial launch of TRUFORMA, we have continually sought ways to optimize our assays based on field performance feedback," said Ashley Wood, PhD, Zomedica's Vice President of Research and Development. "The cortisol assay is vital for veterinarians, allowing them to perform critical tests such as the Low Dose Dexamethasone suppression test with reference lab accuracy, directly in their clinics. By improving what is already one of our most heavily used assays, we expect to further strengthen the TRUFORMA platform's position in the market."
The TRUFORMA system transforms veterinary practices by enabling rapid in-house diagnostics, eliminating the delays associated with sending samples to external labs. This capability is crucial for enhancing patient care and operational efficiency, offering veterinarians immediate results to make timely treatment decisions. The TRUFORMA platform addresses a
"We believe that the enhancements to the cortisol assay make an already valuable tool even better," added T.J. Barclay, Zomedica Professional Services Veterinarian. "The increased dynamic range, which has been improved by over
For more information on Zomedica please visit www.zomedica.com.
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. Zomedica's mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.zomedica.com.
Follow Zomedica
- Email Alerts: http://investors.zomedica.com
- LinkedIn: https://www.linkedin.com/company/zomedica
- Facebook: https://m.facebook.com/zomedica
- X (formerly Twitter): https://twitter.com/zomedica
- Instagram: https://www.instagram.com/zomedica_inc
Cautionary Note Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555
SOURCE: Zomedica Corp.
View the original press release on accesswire.com
FAQ
What is the new enhancement in Zomedica's TRUFORMA platform?
When did Zomedica start shipping the new canine cortisol assay?
How does the enhanced cortisol assay benefit veterinary practices?
What market opportunity does the TRUFORMA platform address?
What improvement has been made in the dynamic range of the cortisol assay?
